Johnson & Johnson has added another piece to the data behind its effort to move Tecvayli into earlier-line therapy for multiple myeloma, including the first relapse setting. In the MajesTEC-9 trial, ...
Jamila Michener ([email protected]), Cornell University, Ithaca, New York. This article examines how racially and economically marginalized tenants built political power in response to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results